Supporting information Lutter et al



Supplementary figure 1. Gating strategy of synovial fluid derived Tregs. (a) Representative gating strategy to sort Tregs derived from synovial fluid (SF). (b) Representative FOXP3 median fluorescence.





Supplementary figure 2. Heterogeneity and phenotypical profile of synovial fluid Tregs. (a) Dimensionality reduction (UMAP) of all sequenced Tregs that passed the quality control. Cluster 5 is of ambiguous composition (e.g. hybrid, transferred extracellular vesicles or doublets) and not included in further analysis. (b) mRNA FOXP3 expression (left) and gene set enrichment of a human core Treg signature¹⁹ (right). Grey means no FOXP3 mRNA expression or Treg signature enrichment, with in blue cells with FOXP3 mRNA (left), and yellow to red increasing shows enrichment of the Treg signature (right). (c) UMAP with the cells colored by phase of the cell cycle; pink = G1, green = G2M, blue = S. Pearson's Chi-squared test revealed no association between the cell cycle phase and the clustering (P = 0.8512). (d) Heatmap of the top 10 upregulated differentially expressed genes, based on log_2 fold change, per cluster. Expression ranges from purple (no raw count mRNA expression) to yellow (presence of mRNA expression of the concerned gene). (e) Similar to (b) but for a gene set upregulated in naïve compared to effector memory human CD4 T-cells (GSE11057).



Supplementary figure 3. Synovial fluid Treg cluster-identifying genes. (a) UMAPs showing the nebulosa density of the selected differentially expressed genes *CCR7*, *LEF1*, *KLF2*, and *TCF7* for cluster 1 Tregs. The nebulosa density (based on kernel density) ranges from blue to yellow, with in yellow the highest kernel density, thus the highest (estimated) expression of the shown gene. (b) Similar to (a) but for *TIGIT*, *IKZF2* (encoding Helios), *LAYN*, and *CTLA4* which are differentially expressed by cluster 2 Tregs. (c) Similar to (a) but for *LGALS1*, *CCR5*, *TNFRSF8*, and *GZMA* which are differentially expressed by cluster 3 Tregs. (d) Similar to (a) but for *CXCL13*, *KLRB1*, *GPR56*, and *PDCD1* which are differentially expressed by cluster 4 Tregs.



Supplementary figure 4. Preferential expansion of Th1-skewed Tregs in synovial fluid. (a) UMAPs showing the nebulosa density of chemokine receptor gene expression combinations (positive expression) that are associated with Tregs that have obtained a T helper (Th)-type co-transcriptional program. Upper row from right to left: *CCR4* for Th2-skewed Tregs, *CCR6*, *CCR4* and *CCR10* expression for Th22-skewed Tregs, and *CCR6* and *CCR4* expression for Th17-skewed Tregs. Lower row from right to left: *CXCR3* and *CCR6* for Th1/Th17-skewed Tregs and *CXCR3* for Th1-skewed Tregs. The nebulosa density (based on kernel density) ranges from blue to yellow, with in yellow the highest kernel density, thus the highest (estimated) expression of the combination of genes.



Supplementary figure 5. Clonal expansion and clonal overlap of synovial fluid-derived Tregs. (a) Dimensionality reduction (UMAP) similar to Figure 1a but of a 10X genomics sequenced synovial fluid (SF)-derived Treg dataset (GSE160097) with the cells colored by cluster. Colors are identical to the clustering of Figure 1a. (b) Morisita, inverse Simpson, Chao and ACE diversity indexes calculated per SF Treg cluster. Each index is a measure for the diversity of the T-cell receptor repertoire per cluster with higher values indicating less diversity of the repertoire. (c) Morisita diversity index for the similarity of the TCR repertoire the four SF Treg clusters and SF CD4 non-Treg cells based on the nucleotide sequence of both the TRA and TRB chain. The scale ranges from 0 to 1, with 0 indicating no overlap and 1 indicating identical repertoires.



Supplementary figure 6. CD161⁺GPR56⁺CXCL13⁺ synovial fluid Tregs are highly differentiated and suppressive cells. (a) Percentages of IFN γ (left), IL-2 (middle) and IL-17 (right) expression within control peripheral blood (PB) GPR56⁻CD161⁻, synovial fluid (SF) GPR56⁻CD161⁻ and SF CXCL13⁺ (GPR56⁺ and/or CD161⁺, and CXCL13⁺) Tregs (CD127^{low}CD25^{high}FOXP3⁺). Control PB n = 7, SF n = 6. Data are representative of two independent experiments. (b) Representative gating strategy to sort CCR7⁺, CCR7⁻ (in PB), CCR7⁻GPR56⁻CD161⁻ (in SF) and CCR7⁻GPR56⁺ and/or CD161⁺ (in SF) Tregs for the suppression assay (gating of Tregs as per Supplementary figure 1a).